Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Propofol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 8/20 | 0.94 |
| ▸ | GABRB1 known ✓ | P18505 | 5/20 | 0.94 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.94 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.94 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.94 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.94 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.94 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.94 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.94 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.94 |
| ▸ | CA1 | P00915 | 2/20 | 0.94 |
| ▸ | CA2 | P00918 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.94 |
| ▸ | LMNA | P02545 | 2/20 | 0.94 |
| ▸ | FAAH | O00519 | 1/20 | 0.94 |
| ▸ | HPGD | P15428 | 1/20 | 0.94 |
| ▸ | TSHR | P16473 | 1/20 | 0.94 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propofol SCHEMBL4458729 | 1.00 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL6040021 | 0.97 | GABRA1 (0.90) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL36245 | 0.97 | GABRA1 (1.00) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL2414429 | 0.97 | GABRA1 (1.00) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL10968616 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL1033835 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL4088686 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL5087474 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL5036811 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL10968613 | 0.94 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-112237907-B | Water purification adsorption material and preparation method and application thereof | 北京化工大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-108601819-B | Amelioration of systemic sclerosis with death receptor agonists | 约翰霍普金斯大学 | 2022-03-15 | — | — | CN | disclosed |
| CN-112689516-A | Use of anti-BCMA chimeric antigen receptors | 细胞基因公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-111479613-A | Methods of administering chimeric antigen receptor immunotherapy | 凯德药业股份有限公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-1744908-A | Amino acid-derived propofol prodrugs, compositions and uses thereof | XENOPORT INC (US) | 2006-03-08 | — | — | CN | disclosed |
| EP-0630261-A4 | NEW CYCLODEXTRINS AND NEW FORMULATED DRUGS. | AUSTRALIAN COMMERCIAL RESEARCH (AU) | 1996-11-06 | — | — | EP | disclosed |
| EP-0630261-A1 | NEW CYCLODEXTRINS AND NEW FORMULATED DRUGS | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993017711-A1 | NEW CYCLODEXTRINS AND NEW FORMULATED DRUGS | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1993-09-16 | — | — | WO | disclosed |